Objective:To study the renal function, peroxidation damage and inflammatory injury after epalrestat combined with alprostadil treatment of early diabetic nephropathy.Methods:90 patients with early diabetic nephropathy...Objective:To study the renal function, peroxidation damage and inflammatory injury after epalrestat combined with alprostadil treatment of early diabetic nephropathy.Methods:90 patients with early diabetic nephropathy treated in our hospital between June 2011 and November 2015 were collected and divided into observation group and control group (n=45) according to the single-blind randomized control method. Observation group received epalrestat combined with alprostadil treatment, control group received alprostadil treatment alone, and the treatment of both groups lasted for 3 months. Before treatment and after 3 months of treatment, turbidimetric immunoassay was used to detect the renal function indexes in peripheral blood, rate method was used to detect the renal function indexes in urine, and ELISA method was used to detect the levels of peroxidation indexes and inflammation indexes.Results:Before treatment, differences in renal function, peroxidation damage and inflammatory damage indexes were not statistically significant between two groups of patients (P>0.05). After 3 months of treatment, creatinine (Scr), cystatin C (CysC),β2 microglobulin (β2-MG), N-acetyl-β-D-glucosaminidase (NAG), reactive oxygen species (ROS), advanced protein oxidation products (AOPPs), interleukin-8 (IL-8), interleukin-27 (IL-27) and procalcitonin (PCT) levels of observation group were lower than those of control group while catalase (CAT), total superoxide dismutase (TSOD), interleukin-4 (IL-4), interleukin-10 (IL-10) and interleukin-13 (IL-13) levels were higher than those of control group (P<0.05). Conclusions:Epalrestat combined with alprostadil can protect the renal function and inhibit the peroxidation damage and inflammatory injury in patients with early diabetic nephropathy.展开更多
Objective:To investigate the effects of erythropoietin combined with percutaneous coronary intervention (PCI) on myocardial damage, vascular endothelial function and neuroendocrine hormone levels in patients with ST-s...Objective:To investigate the effects of erythropoietin combined with percutaneous coronary intervention (PCI) on myocardial damage, vascular endothelial function and neuroendocrine hormone levels in patients with ST-segment elevation myocardial infarction (STEMI).Method:From August 2015 to February 2018, 80 patients with STEMI were selected from our hospital, divided into 2 groups according to admission time, 40 cases in each group, set to observation group and control group, the observation group was treated with erythropoietin combined with PCI, and the control group was treated only with PCI, to compare the degree of myocardial damage, vascular endothelial function and neuroendocrine hormone levels after treatment. Results: At 24 h after surgery, the observed group of cardiac troponin (cTNI), creatine kinase isoenzyme (CK-MB), type I collagen carboxy terminal peptide (ICTP) and ischemic modified albumin (IMA) is lower than the control group,the cystatin-C (Cys-C) level is higher than the control group, the difference was statistically significant (P<0.05);At 1 week after surgery, the levels of endothelin-1 (ET-1) and von Willebrand factor (vWF) in the observation group were lower than the control group, and the level of nitric oxide (NO) was higher than that in the control group, the difference was statistically significant (P<0.05);At 1 week after surgery, the levels of cortisol (Cor), adrenocortical hormone (ACTH), norepinephrine (NE) and Angiotensin II (AngII) in the observation group were lower than in the control group, the difference was statistically significant (P<0.05).Conclusion: Erythropoietin combined with PCI in the treatment of STEMI patients with better clinical effect, can effectively reduce the degree of myocardial damage, protect vascular endothelial cell function, improve the body's neuroendocrine hormone levels, recommend clinical application.展开更多
文摘Objective:To study the renal function, peroxidation damage and inflammatory injury after epalrestat combined with alprostadil treatment of early diabetic nephropathy.Methods:90 patients with early diabetic nephropathy treated in our hospital between June 2011 and November 2015 were collected and divided into observation group and control group (n=45) according to the single-blind randomized control method. Observation group received epalrestat combined with alprostadil treatment, control group received alprostadil treatment alone, and the treatment of both groups lasted for 3 months. Before treatment and after 3 months of treatment, turbidimetric immunoassay was used to detect the renal function indexes in peripheral blood, rate method was used to detect the renal function indexes in urine, and ELISA method was used to detect the levels of peroxidation indexes and inflammation indexes.Results:Before treatment, differences in renal function, peroxidation damage and inflammatory damage indexes were not statistically significant between two groups of patients (P>0.05). After 3 months of treatment, creatinine (Scr), cystatin C (CysC),β2 microglobulin (β2-MG), N-acetyl-β-D-glucosaminidase (NAG), reactive oxygen species (ROS), advanced protein oxidation products (AOPPs), interleukin-8 (IL-8), interleukin-27 (IL-27) and procalcitonin (PCT) levels of observation group were lower than those of control group while catalase (CAT), total superoxide dismutase (TSOD), interleukin-4 (IL-4), interleukin-10 (IL-10) and interleukin-13 (IL-13) levels were higher than those of control group (P<0.05). Conclusions:Epalrestat combined with alprostadil can protect the renal function and inhibit the peroxidation damage and inflammatory injury in patients with early diabetic nephropathy.
文摘Objective:To investigate the effects of erythropoietin combined with percutaneous coronary intervention (PCI) on myocardial damage, vascular endothelial function and neuroendocrine hormone levels in patients with ST-segment elevation myocardial infarction (STEMI).Method:From August 2015 to February 2018, 80 patients with STEMI were selected from our hospital, divided into 2 groups according to admission time, 40 cases in each group, set to observation group and control group, the observation group was treated with erythropoietin combined with PCI, and the control group was treated only with PCI, to compare the degree of myocardial damage, vascular endothelial function and neuroendocrine hormone levels after treatment. Results: At 24 h after surgery, the observed group of cardiac troponin (cTNI), creatine kinase isoenzyme (CK-MB), type I collagen carboxy terminal peptide (ICTP) and ischemic modified albumin (IMA) is lower than the control group,the cystatin-C (Cys-C) level is higher than the control group, the difference was statistically significant (P<0.05);At 1 week after surgery, the levels of endothelin-1 (ET-1) and von Willebrand factor (vWF) in the observation group were lower than the control group, and the level of nitric oxide (NO) was higher than that in the control group, the difference was statistically significant (P<0.05);At 1 week after surgery, the levels of cortisol (Cor), adrenocortical hormone (ACTH), norepinephrine (NE) and Angiotensin II (AngII) in the observation group were lower than in the control group, the difference was statistically significant (P<0.05).Conclusion: Erythropoietin combined with PCI in the treatment of STEMI patients with better clinical effect, can effectively reduce the degree of myocardial damage, protect vascular endothelial cell function, improve the body's neuroendocrine hormone levels, recommend clinical application.
